WASHINGTON, D.C. — Researchers at the National Institute of Quantum Medicine have demonstrated that a glass bead, 0.5 mm in diameter, can be placed in a quantum entangled state with a pulse of laser light, a step the team says could pave the way for novel diagnostic tools.

The experiment, described in a peer‑reviewed article in *Nature Medicine*, involved cooling the bead to 4 kelvin and using a cavity‑enhanced photon source to entangle its vibrational mode with a single photon. Over a 48‑hour observation period, the entanglement persisted for 12 seconds, a duration the authors claim is “orders of magnitude longer than previously reported for macroscopic objects.”

Dr. Emily Carter, lead author and quantum biophysicist, told the press, “Our results show that quantum coherence can be maintained in a solid‑state system that is compatible with existing biomedical imaging platforms.” She added that the technique could eventually enable non‑invasive monitoring of cellular metabolism by detecting subtle shifts in the bead’s quantum state when introduced into tissue.

Clinical translation remains preliminary. An early‑stage feasibility study involving 12 volunteers, each receiving a bead‑based probe under controlled conditions, reported that 8 participants experienced a measurable change in a biomarker linked to oxidative stress, as detected by a correlated change in photon emission. The study, however, was not powered to assess therapeutic outcomes.

The U.S. Food and Drug Administration has granted the protocol an Investigational New Device (IND) designation, allowing limited human testing while it evaluates safety data. FDA officials said the agency is monitoring the work but has not yet granted clearance for diagnostic or therapeutic use.

Key Takeaways

• The entangled glass bead maintains quantum coherence for up to 12 seconds at cryogenic temperatures.
• Preliminary human data suggest a correlation between bead entanglement signatures and oxidative‑stress biomarkers.
• The technology remains investigational; FDA IND status permits limited trials but no commercial deployment.

Patient John Doe, who participated in the feasibility study, noted, “I felt no discomfort, and the researchers could detect a subtle shift that matched my blood test results, which is promising for future monitoring.” While the findings are encouraging, experts caution that broader clinical validation is required before the method can be considered a standard medical tool.